Local Administration of Ginkgolide B Using a Hyaluronan-Based Hydrogel Improves Wound Healing in Diabetic Mice.

Limei Wang, Kedi Xia, Lu Han, Min Zhang, Jihuan Fan, Liu Song, Anqi Liao, Wenyu Wang, Jianfeng Guo
Author Information
  1. Limei Wang: Department of Pharmacy, Jilin Province FAW General Hospital, Changchun, China.
  2. Kedi Xia: Department of Pharmacy, Jilin Province FAW General Hospital, Changchun, China.
  3. Lu Han: Department of Medical Administration, Jilin Province FAW General Hospital, Changchun, China.
  4. Min Zhang: Department of Ophthalmology and Otorhinolaryngology, Jilin Province FAW General Hospital, Changchun, China.
  5. Jihuan Fan: Department of Education and Science Services, Jilin Province FAW General Hospital, Changchun, China.
  6. Liu Song: School of Pharmaceutical Sciences, Jilin University, Changchun, China.
  7. Anqi Liao: School of Pharmaceutical Sciences, Jilin University, Changchun, China.
  8. Wenyu Wang: Department of Thoracic Surgery, Jilin Province FAW General Hospital, Changchun, China.
  9. Jianfeng Guo: School of Pharmaceutical Sciences, Jilin University, Changchun, China.

Abstract

The delayed and incomplete healing of diabetic wounds remains a major concern of global healthcare. The complex biological processes within the diabetic wound, such as chronic inflammation, impaired blood vessel growth and immature collagen remodeling, dramatically cause the failure of current treatments. Thus, emerging therapeutic strategies are highly desirable. Ginkgolide B (GB, a natural product extracted from the leaves of Ginkgo biloba L.) has been applied in the treatment of cerebrovascular and cardiovascular disorders, which is mainly due to the anti-oxidative, anti-inflammatory and proliferative effects. In this study, the role of GB in facilitating the anti-inflammatory and pro-healing effects on diabetic wounds was for the first time confirmed using , and experimental methods. As a consequence, GB was able to significantly achieve the activities of anti-inflammation, re-epithelialization, and pro-angiogenesis. Previously, a hydrogel has been developed using the high molecular weight hyaluronan (hyaluronic acid, HA) in our laboratory. In this study, this hydrogel was utilized for local administration of GB to the full-thickness wounds of diabetic mice. The resultant hydrogel formulation (HA-GB) resulted in the reduction of inflammation, the enhancement of re-epithelialization and angiogenesis, and the modulation of collagens from type III to type I, significantly promoting the healing outcome as compared with a commercially available wound dressing product (INTRASITE Gel). This study confirms a great therapeutic promise of HA-GB for the chronic wounds of diabetic patients.

Keywords

References

  1. Eur J Pharm Biopharm. 2018 Jun;127:244-249 [PMID: 29499300]
  2. ACS Nano. 2020 Apr 28;14(4):4816-4828 [PMID: 32188241]
  3. Nature. 2008 May 15;453(7193):314-21 [PMID: 18480812]
  4. Wound Repair Regen. 2014 Mar-Apr;22(2):151-60 [PMID: 24635168]
  5. Eur Surg Res. 2017;58(1-2):81-94 [PMID: 27974711]
  6. Science. 2014 Nov 21;346(6212):941-5 [PMID: 25414301]
  7. Int J Pharm. 2021 Sep 5;606:120928 [PMID: 34303820]
  8. Int J Mol Sci. 2019 Jul 30;20(15): [PMID: 31366051]
  9. Sci Adv. 2020 Apr 29;6(18):eaaz6579 [PMID: 32494680]
  10. J Dent Res. 2010 Mar;89(3):219-29 [PMID: 20139336]
  11. Eur J Pharm Sci. 2011 Oct 9;44(3):235-40 [PMID: 21855632]
  12. ACS Appl Bio Mater. 2021 Jan 18;4(1):311-324 [PMID: 35014286]
  13. Sci Transl Med. 2014 Dec 3;6(265):265sr6 [PMID: 25473038]
  14. Endocr Metab Immune Disord Drug Targets. 2020;20(1):25-38 [PMID: 31241444]
  15. Int J Pharm. 2021 Mar 15;597:120328 [PMID: 33540013]
  16. Mol Cancer. 2021 Jan 6;20(1):10 [PMID: 33407548]
  17. Int J Pharm. 2020 Mar 15;577:119053 [PMID: 31981707]
  18. Br J Dermatol. 2015 Aug;173(2):370-8 [PMID: 26175283]
  19. PLoS One. 2016 Dec 14;11(12):e0168219 [PMID: 27973574]
  20. Acta Pharm Sin B. 2022 Jan;12(1):378-393 [PMID: 35127393]
  21. CNS Neurosci Ther. 2016 Sep;22(9):729-39 [PMID: 27306494]
  22. Adv Wound Care (New Rochelle). 2016 Mar 1;5(3):119-136 [PMID: 26989578]
  23. Eur J Pharm Biopharm. 2019 Feb;135:61-71 [PMID: 30552972]
  24. Wound Repair Regen. 2014 Sep-Oct;22(5):569-78 [PMID: 24942811]
  25. Adv Ther. 2014 Aug;31(8):817-36 [PMID: 25069580]
  26. Ann Transl Med. 2020 Nov;8(22):1497 [PMID: 33313242]
  27. Adv Wound Care (New Rochelle). 2015 Mar 1;4(3):119-136 [PMID: 25785236]
  28. Wound Repair Regen. 2008 Sep-Oct;16(5):585-601 [PMID: 19128254]
  29. Neural Regen Res. 2018 Jul;13(7):1204-1211 [PMID: 30028328]
  30. Int Immunopharmacol. 2020 Aug;85:106652 [PMID: 32521492]
  31. Adv Drug Deliv Rev. 2018 Mar 1;127:138-166 [PMID: 29626550]
  32. Int J Pharm. 2018 Dec 1;552(1-2):340-351 [PMID: 30300708]
  33. Adv Drug Deliv Rev. 2018 Apr;129:169-193 [PMID: 29501700]
  34. Theranostics. 2018 Feb 7;8(6):1607-1623 [PMID: 29556344]
  35. Clin Plast Surg. 2003 Jan;30(1):37-45 [PMID: 12636214]
  36. J Ethnopharmacol. 2021 Jan 10;264:113279 [PMID: 32810617]
  37. Macromol Biosci. 2018 Jul;18(7):e1800047 [PMID: 29737012]
  38. Eur J Pharm Sci. 2021 Dec 1;167:106021 [PMID: 34571179]
  39. Mater Today Bio. 2021 Sep 21;12:100139 [PMID: 34632363]
  40. Biomaterials. 2012 Nov;33(31):7775-84 [PMID: 22828585]
  41. Biomaterials. 2019 Oct;219:119340 [PMID: 31357007]
  42. Adv Drug Deliv Rev. 2019 Sep - Oct;149-150:2-18 [PMID: 30959068]
  43. Artif Cells Nanomed Biotechnol. 2018 Feb;46(1):26-32 [PMID: 28355923]
  44. Stem Cell Res Ther. 2020 Mar 17;11(1):120 [PMID: 32183899]
  45. Adv Drug Deliv Rev. 2020;161-162:22-41 [PMID: 32745497]
  46. Nat Commun. 2015 Apr 07;6:6748 [PMID: 25849081]
  47. Int J Mol Sci. 2016 Dec 11;17(12): [PMID: 27973441]
  48. J Wound Care. 2013 Aug;22(8):407-8, 410-12 [PMID: 23924840]
  49. J Diabetes Complications. 2016 May-Jun;30(4):746-52 [PMID: 26796432]
  50. J Diabetes Res. 2016;2016:9051426 [PMID: 27595114]
  51. Immunol Cell Biol. 2019 Mar;97(3):258-267 [PMID: 30746824]

Word Cloud

Created with Highcharts 10.0.0diabeticwoundsGBstudyhydrogelhealingwoundchronicinflammationtherapeuticGinkgolideBnaturalproductanti-inflammatoryeffectsusingsignificantlyre-epithelializationhyaluronicacidHA-GBtypedelayedincompleteremainsmajorconcernglobalhealthcarecomplexbiologicalprocesseswithinimpairedbloodvesselgrowthimmaturecollagenremodelingdramaticallycausefailurecurrenttreatmentsThusemergingstrategieshighlydesirableextractedleavesGinkgobilobaLappliedtreatmentcerebrovascularcardiovasculardisordersmainlydueanti-oxidativeproliferativerolefacilitatingpro-healingfirsttimeconfirmedexperimentalmethodsconsequenceableachieveactivitiesanti-inflammationpro-angiogenesisPreviouslydevelopedhighmolecularweighthyaluronanHAlaboratoryutilizedlocaladministrationfull-thicknessmiceresultantformulationresultedreductionenhancementangiogenesismodulationcollagensIIIpromotingoutcomecomparedcommerciallyavailabledressingINTRASITEGelconfirmsgreatpromisepatientsLocalAdministrationUsingHyaluronan-BasedHydrogelImprovesWoundHealingDiabeticMicebiomaterialsdrugdeliveryproductsregenerativemedicine

Similar Articles

Cited By